43
Participants
Start Date
January 29, 2018
Primary Completion Date
June 5, 2020
Study Completion Date
July 1, 2021
Nivolumab
Nivolumab will be given at a fixed dose of 360 mg IV over 30 minutes on Day 8 every 21 days for 4 cycles.
Cisplatin
Cisplatin will be given at 70 mg/m2 IV over 30 minutes on Day 1 every 21 days, and based on treating physician's discretion, split-dose cisplatin can be given at 35 mg/m2 IV Day 1 and Day 8 every 21 days for 4 cycles.
Gemcitabine
Gemcitabine will be given at 1000 mg/m2 IV over 30 minutes on days 1, 8, and every 21 days for 4 cycles.
Masonic Cancer Center - University of Minnesota, Minneapolis
Huntsman Cancer Institute - University of Utah Health, Salt Lake City
Dana-Farber Cancer Institute, Boston
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Masonic Cancer Center, University of Minnesota
OTHER